Sometimes advances in drug development are like London buses: you wait for ages, and then loads turn up at once. This has certainly been the case in the non-alcoholic steatohepatitis (NASH) space recently, with several mid-stage trials yielding positive – or positive-ish – data in the past few months.
Key Takeaways
- Madrigal’s resmetirom is likely to become the first drug approved in NASH later this year
But there is much more to come. Players including Novo Nordisk A/S, Boehringer Ingelheim GmbH, Pfizer Inc....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
